The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

The methodological and reporting quality of systematic reviews from China and the USA are similar

(2017) Jinhui Tian et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus

(2016) Naohide Koyanagawa et al.   ENDOCRINE JOURNAL

Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin

(2016) Jianming Ba et al.   Journal of Diabetes

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

(2016) Changyu Pan et al.   Journal of Diabetes

Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial

(2015) R. Göke et al.   DIABETES & METABOLISM

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

(2015) Markku Laakso et al.   DIABETES CARE

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

(2015) G. Leibowitz et al.   DIABETES OBESITY & METABOLISM

Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach

(2015) Jean Claude Mbanya et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

(2015) Feng Sun et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

(2015) Wolfgang Kothny et al.   DIABETOLOGIA

FO022EFFECTS OF LINAGLIPTIN ON EARLY ALTERATIONS OF RENAL ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE-2 DIABETES

(2015) Roland E. Schmieder et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

(2015) Yun-Zhao Tang et al.   Diabetology & Metabolic Syndrome

Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial

(2015) Weiqing Wang et al.   Journal of Diabetes

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

Efficacy and Safety Comparison of Add-on Therapy with Liraglutide, Saxagliptin and Vildagliptin, All in Combination with Current Conventional Oral Hypoglycemic Agents Therapy in Poorly Controlled Chinese Type 2 Diabetes

(2014) C.-J. Li et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

(2014) K. Esposito et al.   BMJ Open

Reporting of results from network meta-analyses: methodological systematic review

(2014) A. Bafeta et al.   BMJ-British Medical Journal

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus 中国2型糖尿病患者使用磺脲类药物联合维格列汀可改善血糖控制且无低血糖及体重增加

(2014) Wenying Yang et al.   Journal of Diabetes

Hypoglycemia: Minimizing its Impact in Type 2 Diabetes

(2013) Etie Moghissi et al.   Endocrine Practice

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Assessing key assumptions of network meta-analysis: a review of methods

(2013) Sarah Donegan et al.   Research Synthesis Methods

Efficacy and Safety of Linagliptin in Elderly Patients (≥70 Years) With Type 2 Diabetes

(2012) Anthony Barnett et al.   Canadian Journal of Diabetes

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

(2012) Masaya Sakamoto et al.   Cardiovascular Diabetology

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study

(2012) B. Guerci et al.   DIABETES & METABOLISM

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus

(2012) C. Pan et al.   DIABETES OBESITY & METABOLISM

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

(2012) D. Singh-Franco et al.   DIABETES OBESITY & METABOLISM

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients

(2012) Giuseppe Derosa et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study

(2012) Giuseppe Derosa et al.   EXPERT OPINION ON PHARMACOTHERAPY

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING

Glucagon-like peptide-1 receptor agonists and their effects on weight reduction

(2012) Shyi-Jang Shin   Journal of Diabetes Investigation

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†

(2012) Wenying YANG et al.   Journal of Diabetes

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

(2012) Thomas Rauch et al.   Diabetes Therapy

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

(2011) Yoshiharu Horie et al.   CLINICAL THERAPEUTICS

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

(2011) Nir Barzilai et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

(2011) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

(2011) K. R. Gerrald et al.   DIABETES OBESITY & METABOLISM

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

(2011) R. Kawamori et al.   DIABETES OBESITY & METABOLISM

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

(2011) L. Cai et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

(2009) Abd A. Tahrani et al.   ADVANCES IN THERAPY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

(2008) A. J. Garber et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM